Art. -Nr.: HY-146131

ATG7-IN-3

Kundenbewertung

Based on 1 Customer Validation

ATG7-IN-3 (Compound 18) is a potent ATG7 inhibitor with an IC₅₀ of 0.048 μM. ATG7-IN-3 inhibits Autophagy. ATG7-IN-3 inhibits the formation of LC3B puncta. ATG7-IN-3 can be used in the researches of glioma and colon cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.17%
CAS. Nr.: 2226229-76-9
Formel: C₁₁H₁₆N₆O₅S₂
Molecular Weight:376.41

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

ATG7-IN-3 Chemical Structure

CAS. Nr.: 2226229-76-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC₅₀: 0.048 ± 0.022 μM (ATG7), 0.280 ± 0.051 μM (Thioester), 0.938 ± 0.231 μM (LC3B)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
NCI-H1650	EC₅₀	10.4 μM Compound: 18	Antiproliferative activity against human H1650 cells assessed as reduction in cell viability after 72 hrs by cell titer glow assay Antiproliferative activity against human H1650 cells assessed as reduction in cell viability after 72 hrs by cell titer glow assay	[PMID: 32912429]
SK-OV-3	EC₅₀	>20 μM Compound: 18	Induction of autophagy in human SKOV3 cells assessed as accumulation of NRB1 by immunofluorescence assay Induction of autophagy in human SKOV3 cells assessed as accumulation of NRB1 by immunofluorescence assay	[PMID: 32912429]
SK-OV-3	EC₅₀	3 μM Compound: 18	Induction of autophagy in human SKOV3 cells assessed as accumulation of p62 by immunofluorescence assay Induction of autophagy in human SKOV3 cells assessed as accumulation of p62 by immunofluorescence assay	[PMID: 32912429]

In Vitro

ATG7-IN-3 inhibits ATG7 with an IC₅₀ value of 0.048 μM^[1].
ATG7-IN-3 inhibits endogenous LC3B puncta formation in H4 cells (glioma cells) with an IC₅₀ of 0.938 μM^[1].
ATG7-IN-3 induces p62 accumulation in SKOV-3 cells (p62 EC₅₀ of 3.0 μM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

ATG7-IN-3 (150 mg/kg; s.c.) regulates autophagy markers LC3B and NBR1 in HCT-116 xenografted mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 2226229-76-9
Appearance Solid
Molecular Weight 376.41
Formel C₁₁H₁₆N₆O₅S₂
Color White to off-white
SMILES

CSC1=NN([C@]2([H])O[C@@H]([C@H](C2)O)COS(N)(=O)=O)C3=NC=NC(N)=C31
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (265.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6567 mL

13.2834 mL

26.5668 mL

5 mM

0.5313 mL

2.6567 mL

5.3134 mL

10 mM

0.2657 mL

1.3283 mL

2.6567 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Huang SC, et al. Discovery and optimization of pyrazolopyrimidine sulfamates as ATG7 inhibitors. Bioorg Med Chem. 2020 Oct 1;28(19):115681. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6567 mL	13.2834 mL	26.5668 mL	66.4169 mL
	5 mM	0.5313 mL	2.6567 mL	5.3134 mL	13.2834 mL
	10 mM	0.2657 mL	1.3283 mL	2.6567 mL	6.6417 mL
	15 mM	0.1771 mL	0.8856 mL	1.7711 mL	4.4278 mL
	20 mM	0.1328 mL	0.6642 mL	1.3283 mL	3.3208 mL
	25 mM	0.1063 mL	0.5313 mL	1.0627 mL	2.6567 mL
	30 mM	0.0886 mL	0.4428 mL	0.8856 mL	2.2139 mL
	40 mM	0.0664 mL	0.3321 mL	0.6642 mL	1.6604 mL
	50 mM	0.0531 mL	0.2657 mL	0.5313 mL	1.3283 mL
	60 mM	0.0443 mL	0.2214 mL	0.4428 mL	1.1069 mL
	80 mM	0.0332 mL	0.1660 mL	0.3321 mL	0.8302 mL
	100 mM	0.0266 mL	0.1328 mL	0.2657 mL	0.6642 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

ATG7-IN-3

MCE Bioactive Compound Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

ATG7-IN-3 Related Classifications

HY-146131 Related Classifications